Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

HKSE 0874.HK

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT for the year ending December 31, 2023: USD 782.66 M

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT is USD 782.66 M for the year ending December 31, 2023, a 26.85% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT for the year ending December 31, 2022 was USD 616.99 M, a -23.74% change year over year.
  • Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT for the year ending December 31, 2021 was USD 809.08 M, a 30.86% change year over year.
  • Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT for the year ending December 31, 2020 was USD 618.27 M, a 30.12% change year over year.
  • Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited EBIT for the year ending December 31, 2019 was USD 475.15 M, a -18.77% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
SV Wall Street
HKSE: 0874.HK

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Description

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Similar companies

1065.HK

Tianjin Capital Environmental Protection Group Company Limited

USD 0.42

0.60%

0921.HK

Hisense Home Appliances Group Co., Ltd.

USD 3.47

0.54%

0553.HK

Nanjing Panda Electronics Company Limited

USD 0.40

0.97%

0995.HK

Anhui Expressway Company Limited

USD 1.35

-0.21%

0719.HK

Shandong Xinhua Pharmaceutical Company Limited

USD 0.73

0.16%

StockViz Staff

February 3, 2025

Any question? Send us an email